Lifemel Honey to Reduce Leucopenia During Chemotherapy

Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00243165

Enrollment

Registered

2005-10-21

Start date

2005-11-30

Completion date

Unknown

Last updated

2009-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer, honey, myelosuppression, chemotherapy

Brief summary

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Interventions

BEHAVIORALLifemel honey intake every day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* breast cancer patient treated with adjuvant chemotherapy * PS = 2 or less

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Prevention of myelotoxicity-every week during chemotherapy.	—

Contacts

Primary ContactGeorgeta Fried, MD

g_fried@rambam.health.gov.il972-4-8543018

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026